A Small Chimpanzee Study Found Persistent THC Task Effects Without Detected Tolerance

A 1973 study of five chimpanzees found persistent effects on delayed matching-to-sample performance without detected tolerance during the tested THC regimens. It also reported no observed long-term behavioral effects after the regimens ended.

Accuracy and speed were followed during exposure

The animals received two dose regimens lasting several weeks. Both significantly affected task accuracy and speed. Repeated exposure did not produce the tolerance seen in some other animal tasks, demonstrating that tolerance is not an inevitable result on every endpoint.

Cessation was a separate observation period

The report's absence of observed long-term effects after treatment should be retained alongside the persistent effects during dosing. It does not negate the exposure-period deficit. Conversely, deficits during exposure do not by themselves prove permanent injury after cessation.

A five-animal task study has narrow reach

The abstract does not establish a universal primate response, provide a comprehensive assessment of every cognitive function or identify why tolerance failed to develop. Species, task demands, dose and observation period all matter when comparing it with studies reporting recovery.

The experiment is useful counterevidence to a blanket claim that chronic THC always eliminates performance effects. It cannot establish permanent damage or predict an individual's impairment. The appropriate account includes both the during-treatment tolerance null and the post-treatment behavioral observation.

Related: interpreting cannabis tolerance claims.

Research cited

Ferraro DP; Grilly DM. Lack of tolerance to 9 -tetrahydrocannabinol in chimpanzees. Science (New York, N.Y.) (1973). doi:10.1126/science.179.4072.490. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us